Targeting the nucleolus for cancer intervention
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Cellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“Further, posttranslational modification and association with co-factors mediate p53 activity towards its transcriptional targets (reviewed in [129,130]).”
BackgroundMotzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 1×
“and the new-generation ‘rapalog’ everolimus, which is FDA-approved for the treatment of renal cell carcinoma and advanced ER-positive/ HER2-negative breast cancer [247,248], displays potent anti-tumor activity in a MYC-driven lymphoma model characterized by enhanced Pol I transcription [1,249].”
BackgroundEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“and the new-generation ‘rapalog’ everolimus, which is FDA-approved for the treatment of renal cell carcinoma and advanced ER-positive/ HER2-negative breast cancer [247,248], displays potent anti-tumor activity in a MYC-driven lymphoma model characterized by enhanced Pol I transcription [1,249].”
BackgroundThe economics of ribosome biosynthesis in yeast
Warner, J. R. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01460-7 · Cited by 1,933
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · cited 1×
“For example, RAS and RAF are mutated in 30% and 6-7% of human cancers respectively (reviewed in [71], [72] and [73]).”
BackgroundThe RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · cited 1×
“Further, downstream targets of p53-dependent stress signaling also negatively regulate Pol I transcription, including activation of pRb (reviewed in [86]), or repression of MYC [87].”
Background
Cited by
Metal complex interactions with DNA
Pages, B. J., Ang, D. L., Wright, E. P., & Aldrich-Wright, J. R. (2015) · Dalton Transactions · doi:10.1039/c4dt02700k · Cited by 459
Baßler, J., & Hurt, E. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-110817 · Cited by 414
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00728-8 · Cited by 408
Self-citationHua, X.-W., Bao, Y.-W., & Wu, F.-G. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b19549 · Cited by 339
Nucleolar stress with and without p53
James, A., Wang, Y., Raje, H., Rosby, R., & DiMario, P. (2014) · Nucleus · doi:10.4161/nucl.32235 · Cited by 285
Nucleolar Stress: hallmarks, sensing mechanism and diseases
Yang, K., Yang, J., & Yi, J. (2018) · Cell Stress · doi:10.15698/cst2018.06.139 · Cited by 283
Kasteri, J., Das, D., Zhong, X., Persaud, L., Francis, A., Muharam, H., & Sauane, M. (2018) · Cancers · doi:10.3390/cancers10050133 · Cited by 24
Chang, C. Y.-Y., Tseng, C.-C., Lai, M.-T., Chiang, A.-J., Lo, L.-C., Chen, C.-M., Yen, M.-J., Sun, L., Yang, L., Hwang, T., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0248168 · Cited by 20
“Clinical observations in cancer therapy have provided convincing evidence to suggest the hyperactive nucleolus as an emerging target for chemotherapeutic intervention [44,45].”
BackgroundConserved nucleolar stress at the onset of cell death
Golstein, P. (2017) · The FEBS Journal · doi:10.1111/febs.14095 · Cited by 7
Metadata
- Authors
- Quin, J. E., Devlin, J. R., Cameron, D., Hannan, K. M., Pearson, R. B., & Hannan, R. D.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 1842
- Issue
- 6
- Pages
- 802-816
- ISSN
- 0925-4439 (ISSN-L)
- OpenAlex
- W1981188497
- Cited by
- 226
- References
- 32
- FWCI
- 10.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.